Natera, Inc. NTRA
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- +80.85%
- 1 year
- +114.42%
- Open
- 425.55
- Prev close
- 436.00
- Mkt cap
- 59.72B
- Vol
- 2.43M
- Avg vol
- 1.52M
- EPS
- -1.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 408.32
- High
- 431.26
- Forward P/E
- -2329.62
- Beta
- 1.50
- Short ratio
- 3.13
- Inst. own
- 96.69%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 375.27
- 200-d avg
- 265.27
- 1y target
- 416.39
MAX chart
Events in this range
- Aug 7, 2025Earnings: -0.74; estimate -0.61546; surprise -20.24%
- Nov 6, 2025Earnings: -0.64; estimate -0.38569; surprise -65.94%
- May 7, 2026Earnings: -0.56; estimate -0.54222; surprise -3.28%
- Aug 6, 2026Earnings: -0.47; estimate -0.49394; surprise 4.85%
- Oct 7, 2026Rating: Barclays · Overweight → Overweight
- Nov 5, 2026Earnings: —; estimate -0.28124; surprise —%
Signals (44)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Jun 1, 2026 | 5 months ago |
| RSI: Overbought | Nov 1, 2025 | 12 months ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 1, 2025 | 1 year ago |
| RSI: Overbought | Nov 1, 2024 | 1 year ago |
| RSI: Overbought | Aug 1, 2024 | 2 years ago |
| RSI: Overbought | May 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 1, 2023 | 2 years ago |
| SMA: Bullish | Nov 1, 2023 | 3 years ago |
| SMA: Bearish | Sep 1, 2023 | 3 years ago |
| SMA: Bullish | Aug 1, 2023 | 3 years ago |
| SMA: Bearish | Jul 1, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 1, 2023 | 3 years ago |
| SMA: Bullish | Jan 1, 2023 | 3 years ago |
| SMA: Bearish | Jan 1, 2022 | 4 years ago |
| SMA: Bearish | Nov 1, 2021 | 5 years ago |
| MACD: Sell Signal | Nov 1, 2021 | 5 years ago |
| RSI: Overbought | Jun 1, 2021 | 5 years ago |
| RSI: Overbought | Aug 1, 2020 | 6 years ago |
| RSI: Overbought | Jun 1, 2020 | 6 years ago |
| SMA: Bullish | Apr 1, 2020 | 6 years ago |
| SMA: Bearish | Mar 1, 2020 | 6 years ago |
| RSI: Overbought | Oct 1, 2019 | 7 years ago |
| SMA: Bullish | May 1, 2019 | 7 years ago |
| SMA: Bearish | Apr 1, 2019 | 7 years ago |
| SMA: Bullish | Mar 1, 2019 | 7 years ago |
| MACD: Buy Signal | Mar 1, 2019 | 7 years ago |
| MACD: Sell Signal | Feb 1, 2019 | 7 years ago |
| SMA: Bearish | Nov 1, 2018 | 8 years ago |
| RSI: Overbought | Aug 1, 2018 | 8 years ago |
| SMA: Bullish | Apr 1, 2018 | 8 years ago |
| SMA: Bullish | Apr 1, 2018 | 8 years ago |
| SMA: Bearish | Feb 1, 2018 | 8 years ago |
| SMA: Bullish | Jan 1, 2018 | 8 years ago |
| SMA: Bearish | Nov 1, 2017 | 9 years ago |
| SMA: Bullish | Aug 1, 2017 | 9 years ago |
| SMA: Bearish | Jul 1, 2017 | 9 years ago |
| SMA: Bullish | May 1, 2017 | 9 years ago |
| SMA: Bearish | Jan 1, 2017 | 9 years ago |
| SMA: Bullish | Nov 1, 2016 | 10 years ago |
| SMA: Bearish | Oct 1, 2016 | 10 years ago |
| SMA: Bullish | Sep 1, 2016 | 10 years ago |
| SMA: Bearish | Aug 1, 2016 | 10 years ago |
| SMA: Bullish | May 1, 2016 | 10 years ago |
Key statistics
- Market cap
- 59.72B
- Enterprise value
- 61.99B
- Trailing P/E
- 0.00
- Forward P/E
- -2329.62
- PEG ratio
- 0.00
- Price / sales
- 22.06
- Price / book
- 32.67
- EPS (TTM)
- -1.35
- Beta
- 1.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -7.11%
- Revenue (TTM)
- 2.71B
- Revenue growth
- 37.70%
- Free cash flow
- 104.03M
- Total cash
- 1.09B
- Total debt
- 238.49M
- Return on equity
- -12.54%
- Shares outstanding
- 144.14M
- Short % of float
- 4.18%
- 50-day average
- 375.27
- 200-day average
- 265.27
Analyst view
Consensus: strong buy
- Target (low)
- 280.00
- Target (mean)
- 416.39
- Target (high)
- 500.00
- Strong buy4
- Buy17
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.28026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.28124 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.49394 | -0.47 | +0.02 | +4.85% |
| May 7, 2026 | Mar 31, 2026 | -0.54222 | -0.56 | -0.02 | -3.28% |
| Feb 26, 2026 | Dec 31, 2025 | -0.51207 | 0.35 | +0.86 | +168.35% |
| Nov 6, 2025 | Sep 30, 2025 | -0.38569 | -0.64 | -0.25 | -65.94% |
| Aug 7, 2025 | Jun 30, 2025 | -0.61546 | -0.74 | -0.12 | -20.24% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | BTIG | main | Buy | Buy |
| Oct 19, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 14, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 13, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
About Natera, Inc.
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- natera.com
News
- Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
- Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
- Natera, Shake Shack, eBay And More On CNBC's ‘Final Trades'
- Natera, Shake Shack, eBay And More On CNBC’s ‘Final Trades’
- 1,598 Shares of Natera, Inc. $NTRA Purchased by Bosman Wealth Management LLC
- Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- Parnassus Mid Cap Growth Fund: Q3 2026 Performance Review
- Alger Dynamic Opportunities Fund Q3 2026 Portfolio Update
- NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results?
- Weatherbie Specialized Growth Fund Q3 2026 Portfolio Update
Your note
Sign in to keep a note on NTRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAYNES ROY D | Director | Stock Award(Grant) | Jun 25, 2026 | 20,158 |
| BOTHA ROELOF FREDERICK | Director | Stock Award(Grant) | Jun 25, 2026 | 1,080,780 |
| BROPHY MICHAEL BURKES | Chief Financial Officer | Sale | Aug 3, 2026 | 51,637 |
| CHAPMAN STEVEN LEONARD | Chief Executive Officer | Sale | Oct 27, 2026 | 91,232 |
| FESKO JOHN | President | Sale | Aug 9, 2026 | 197,257 |
| HEALY JAMES I | Director | Stock Award(Grant) | Apr 24, 2025 | 1,596,540 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JPMORGAN CHASE & CO | 8.93% | 12,865,346 | 5.33B | Jun 29, 2026 |
| Blackrock Inc. | 7.57% | 10,914,608 | 4.52B | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 6.26% | 9,021,895 | 3.74B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.32% | 6,228,216 | 2.58B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.01% | 5,782,640 | 2.40B | Jun 29, 2026 |
| FMR, LLC | 3.78% | 5,451,396 | 2.26B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JPMorgan Trust II-JPMorgan Large Cap Growth Fund | 3.85% | 5,550,940 | 2.30B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.00% | 4,320,351 | 1.79B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.16% | 3,119,416 | 1.29B | Jun 29, 2026 |
| Fidelity Contrafund | 1.41% | 2,028,432 | 840.38M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.25% | 1,799,359 | 745.47M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.14% | 1,642,271 | 680.39M | Jun 29, 2026 |